Results of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial, which compared dapagliflozin (10 mg once daily) to placebo, found that dapagliflozin was associated with a 44% reduction in a composite of adverse kidney outcomes and a 29% reduction in death from cardiovascular causes or hospitalization for heart failure
Thus, our cellular analyses provide evidence that the DNA binding activity of PDS5B is important for HR, DNA damage repair, and the maintenance of genome stability
Natalie Crawford, who's an OBGYN specializing in fertility, we talked a lot about LH and FSH
Ordinarily, in someone who has not lost weight on Ozempic-type drugs, if theres a complication [related to healing] after surgery, we see it as early as week two, and we tend to see good healing between weeks four and six. But for GLP-1 patients, incisions will sometimes reopen in spots